Compare Regeneron Pharmaceuticals Inc (REGN) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Uber Technologies Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Uber Technologies Inc trades at $70.52 (market cap $145.65B). The key difference: Uber Technologies Inc is far larger — about 2.1× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| REGN | UBER | |
|---|---|---|
Market Cap | $70.79B | $145.65B |
Sector | Health | Industrials |
52-Week High | $812.27 | $100.10 |
52-Week Low | $545.46 | $68.61 |
Enterprise Value | $64.74B | $151.98B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Uber's stock trades at $72.17, down 0.4% on the day, with a bearish technical signal from moving averages. The company reported strong revenue growth to $52.02B in 2025 and a net income of $10.05B, though earnings have been mixed with a recent miss in Q4 2025. Positive cash flow from operations reached $10.10B, and analyst sentiment remains overwhelmingly bullish with an 81.67% buy rating and a consensus price target of $107.64. Recent news highlights strategic moves in autonomous vehicles, including robotaxi pilots in Madrid and Munich.
The outlook for Uber is positive due to robust revenue growth, expanding profitability, and strong analyst support, but risks include competitive pressures in key markets like India, execution challenges in autonomous driving initiatives, and potential cost overruns from AI investments. The stock offers upside potential if it meets earnings expectations and successfully scales new technologies, though investors should monitor competitive dynamics and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
